Sam Moussa
Gastroenterology · Tucson, AZNPI 1396730180
Payments from drug & device makers
Across 449 payments — averaging $8771.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.5M
- Madrigal Pharmaceuticals$1.1M
- Regeneron$401K
- AbbVie$216K
- Takeda Pharmaceuticals U.S.A., Inc.$204K
- Boehringer Ingelheim International GmbH$189K
- plus $323K from 13 others
Across 9 payments — averaging $205.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $1,480,295 |
| Madrigal Pharmaceuticals | 76 | $1,124,824 |
| Regeneron | 57 | $401,384 |
| AbbVie | 64 | $215,587 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $203,758 |
| Boehringer Ingelheim International GmbH | 89 | $189,336 |
| Ironwood Pharmaceuticals, Inc | 20 | $119,728 |
| Shire North American Group Inc | 25 | $82,472 |
| Novo Nordisk AS | 43 | $55,341 |
| Bristol Myers Squibb | 5 | $30,498 |
| Merck | 4 | $27,515 |
| Olympus America Inc. | 1 | $2,881 |
| Fujifilm Healthcare Americas Corporation | 3 | $1,704 |
| Bausch Health US, LLC | 3 | $1,500 |
| Vanda Pharmaceuticals Inc. | 1 | $800 |
| Astrazeneca UK Limited | 7 | $606 |
| Abbott | 1 | $48 |
| Alfasigma USA, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$3,938,301 in reported general payments places this provider in the 95th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Tucson
- Bassel KissoTucson$2.3M
- Fadi DeebTucson$1.5M
- Sasha TalebanTucson$744K
- Rehan IftikharTucson$479K
- Craig GrossTucson$256K
- Gary GoldsteinTucson$177K
- Rizwan SafdarTucson$98K
- Gary GottliebTucson$91K
- Joseph DavisChandler$7.4M
- Manreet KaurScottsdale$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.